Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (341-350 of 373) with videos related to

Pageof 38
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 12, 2025
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativaJohn R Ingram, Magdalena B Wozniak, Anna Passera, et al.
Frontiers in Immunology|February 23, 2026
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyStella X Chen, Bruna Galvao de O Wafae, Sydney Look-Why, et al.
JAMA Network Open|December 8, 2022
Evaluation of Telehealth Visit Attendance After Implementation of a Patient Navigator ProgramOren J Mechanic, Emma M Lee, Heidi M Sheehan, et al.
International Journal of Dermatology|August 21, 2025
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 StudiesAfsaneh Alavi, Ziad Reguiai, Gregor B E Jemec, et al.
The British Journal of Dermatology|March 28, 2019
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trialsG B E Jemec, M M Okun, S B Forman, et al.
Plos One|November 29, 2021
Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatmentJoseph D Sherrill, Deborah Finlay, Robert L Binder, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
JAMA|August 25, 2011
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsCaitriona Ryan, Craig L Leonardi, James G Krueger, et al.
Pageof 38

Showing results (341-350 of 373) with videos related to

Sort By:
Pageof 38
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 12, 2025
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativaJohn R Ingram, Magdalena B Wozniak, Anna Passera, et al.
Frontiers in Immunology|February 23, 2026
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational studyStella X Chen, Bruna Galvao de O Wafae, Sydney Look-Why, et al.
JAMA Network Open|December 8, 2022
Evaluation of Telehealth Visit Attendance After Implementation of a Patient Navigator ProgramOren J Mechanic, Emma M Lee, Heidi M Sheehan, et al.
International Journal of Dermatology|August 21, 2025
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 StudiesAfsaneh Alavi, Ziad Reguiai, Gregor B E Jemec, et al.
The British Journal of Dermatology|March 28, 2019
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trialsG B E Jemec, M M Okun, S B Forman, et al.
Plos One|November 29, 2021
Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatmentJoseph D Sherrill, Deborah Finlay, Robert L Binder, et al.
Dermatology and Therapy|May 15, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Jacek C Szepietowski, Lukasz Matusiak, et al.
JAMA|August 25, 2011
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsCaitriona Ryan, Craig L Leonardi, James G Krueger, et al.
Pageof 38